PL202224B1 - Stała kompozycja farmaceutyczna zawierająca związek HSA - Google Patents
Stała kompozycja farmaceutyczna zawierająca związek HSAInfo
- Publication number
- PL202224B1 PL202224B1 PL353968A PL35396800A PL202224B1 PL 202224 B1 PL202224 B1 PL 202224B1 PL 353968 A PL353968 A PL 353968A PL 35396800 A PL35396800 A PL 35396800A PL 202224 B1 PL202224 B1 PL 202224B1
- Authority
- PL
- Poland
- Prior art keywords
- mas
- less
- composition
- preferably less
- solution
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- LFQXEZVYNCBVDO-PBJLWWPKSA-N 4,4-dimethyl-5alpha-cholesta-8,14,24-trien-3beta-ol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CCC1=C2CC[C@]2(C)[C@@H]([C@@H](CCC=C(C)C)C)CC=C21 LFQXEZVYNCBVDO-PBJLWWPKSA-N 0.000 claims abstract description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 239000003960 organic solvent Substances 0.000 claims abstract description 9
- 239000007787 solid Substances 0.000 claims abstract description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 26
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 26
- 210000000287 oocyte Anatomy 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 238000000354 decomposition reaction Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 abstract description 3
- 210000002966 serum Anatomy 0.000 abstract description 3
- 102000007562 Serum Albumin Human genes 0.000 abstract description 2
- 108010071390 Serum Albumin Proteins 0.000 abstract description 2
- 230000004720 fertilization Effects 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 34
- 239000002609 medium Substances 0.000 description 9
- 239000000654 additive Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 6
- 230000000996 additive effect Effects 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 239000012736 aqueous medium Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 230000021121 meiosis Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RCFJIAQLIRLKEN-BYPYZUCNSA-N (2s)-2-hydrazinyl-4-methylsulfanylbutanoic acid Chemical compound CSCC[C@H](NN)C(O)=O RCFJIAQLIRLKEN-BYPYZUCNSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 108010006578 follitropin alfa Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 229940057854 gonal f Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000004508 polar body Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002342 ribonucleoside Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199901308 | 1999-09-16 | ||
| PCT/DK2000/000500 WO2001019354A2 (en) | 1999-09-16 | 2000-09-11 | Composition for ivf |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL353968A1 PL353968A1 (en) | 2003-12-15 |
| PL202224B1 true PL202224B1 (pl) | 2009-06-30 |
Family
ID=8103409
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL353968A PL202224B1 (pl) | 1999-09-16 | 2000-09-11 | Stała kompozycja farmaceutyczna zawierająca związek HSA |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6844313B1 (no) |
| EP (1) | EP1216059B1 (no) |
| JP (1) | JP2003509365A (no) |
| KR (1) | KR100757909B1 (no) |
| CN (1) | CN1222319C (no) |
| AT (1) | ATE306942T1 (no) |
| AU (1) | AU781994B2 (no) |
| BR (1) | BR0014058A (no) |
| CA (1) | CA2382908A1 (no) |
| CZ (1) | CZ2002591A3 (no) |
| DE (1) | DE60023324T2 (no) |
| ES (1) | ES2252048T3 (no) |
| HU (1) | HUP0202630A3 (no) |
| IL (1) | IL148234A0 (no) |
| MX (1) | MXPA02002439A (no) |
| NO (1) | NO323694B1 (no) |
| PL (1) | PL202224B1 (no) |
| RU (1) | RU2263516C2 (no) |
| UA (1) | UA78183C2 (no) |
| WO (1) | WO2001019354A2 (no) |
| ZA (1) | ZA200201383B (no) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0200201A3 (en) * | 1999-02-26 | 2002-06-28 | Schering Ag | Meiosis activating sterol augments implantation rate |
| CZ2002591A3 (cs) | 1999-09-16 | 2002-08-14 | Novo Nordisk A/S | Pevný produkt, prostředek, vodný roztok a zaváděcí systém |
| MXPA02007818A (es) * | 2000-02-25 | 2002-10-23 | Schering Ag | Tasa de implantacion mejorada utilizando ff-mas. |
| US6988613B2 (en) | 2001-02-06 | 2006-01-24 | Novo Nordisk A/S | Composition for IVF |
| EP1245572A1 (en) | 2001-03-26 | 2002-10-02 | Schering Aktiengesellschaft | Aminosterol compounds, their use in the preparation of meiosis-regulating medicaments and method for their preparation |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4175074A (en) | 1976-08-23 | 1979-11-20 | Deshmukh Arvind D | Serum-soluble cholesterol compounds and method for their preparation |
| US4751219A (en) | 1985-02-05 | 1988-06-14 | Nederlandse Centrale Organisatie Voor Toegepast-Natuur-Wetenschappelijk Onderzoek | Synthetic glycolipides, a process for the preparation thereof and several uses for these synthetic glycolipides |
| AU4312489A (en) * | 1988-09-23 | 1990-04-18 | Cetus Corporation | Lipid microemulsions for culture media |
| DE4221880A1 (de) | 1992-07-03 | 1994-01-05 | Alfatec Pharma Gmbh | Feste und flüssige Lösungen von schwer wasserlöslichen Arzneistoffen |
| EP0674506B1 (en) * | 1992-12-02 | 2000-08-23 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
| US5716777A (en) * | 1994-06-23 | 1998-02-10 | Novo Nordisk A/S | Regulation of meiosis using sterols |
| US6281015B1 (en) * | 1994-12-16 | 2001-08-28 | Children's Medical Center Corp. | Localized delivery of factors enhancing survival of transplanted cells |
| JPH11501806A (ja) | 1995-03-06 | 1999-02-16 | ノボ ノルディスク アクティーゼルスカブ | 減数分裂の刺激 |
| CN1191543A (zh) | 1995-06-23 | 1998-08-26 | 诺沃挪第克公司 | 减数分裂调控化合物 |
| GB9625175D0 (en) * | 1996-12-04 | 1997-01-22 | Medi Cult As | Serum-free cell culture media |
| AU746878B2 (en) * | 1996-12-20 | 2002-05-02 | Novo Nordisk A/S | Meiosis regulating compounds |
| DK0988312T3 (da) | 1997-06-04 | 2002-07-15 | Akzo Nobel Nv | 17beta-allyloxy(thio)alkyl-androstanderivater til modulering af meiose |
| HUP9701554D0 (en) | 1997-09-18 | 1997-11-28 | Human Oltoanyagtermeloe Gyogys | Pharmaceutical composition containing plazma proteins |
| CA2333320A1 (en) | 1998-05-26 | 1999-12-02 | Schering Aktiengesellschaft | Treatment of infertility with camp-increasing compounds alone or in combination with at least one meiosis-stimulating compound |
| HUP0200201A3 (en) * | 1999-02-26 | 2002-06-28 | Schering Ag | Meiosis activating sterol augments implantation rate |
| CZ2002591A3 (cs) | 1999-09-16 | 2002-08-14 | Novo Nordisk A/S | Pevný produkt, prostředek, vodný roztok a zaváděcí systém |
-
2000
- 2000-09-11 CZ CZ2002591A patent/CZ2002591A3/cs unknown
- 2000-09-11 CA CA002382908A patent/CA2382908A1/en not_active Abandoned
- 2000-09-11 DE DE60023324T patent/DE60023324T2/de not_active Expired - Fee Related
- 2000-09-11 JP JP2001522989A patent/JP2003509365A/ja active Pending
- 2000-09-11 BR BR0014058-9A patent/BR0014058A/pt not_active Application Discontinuation
- 2000-09-11 ES ES00958274T patent/ES2252048T3/es not_active Expired - Lifetime
- 2000-09-11 KR KR1020027003526A patent/KR100757909B1/ko not_active IP Right Cessation
- 2000-09-11 AT AT00958274T patent/ATE306942T1/de not_active IP Right Cessation
- 2000-09-11 WO PCT/DK2000/000500 patent/WO2001019354A2/en active IP Right Grant
- 2000-09-11 MX MXPA02002439A patent/MXPA02002439A/es active IP Right Grant
- 2000-09-11 PL PL353968A patent/PL202224B1/pl not_active IP Right Cessation
- 2000-09-11 AU AU69850/00A patent/AU781994B2/en not_active Ceased
- 2000-09-11 IL IL14823400A patent/IL148234A0/xx unknown
- 2000-09-11 EP EP00958274A patent/EP1216059B1/en not_active Expired - Lifetime
- 2000-09-11 RU RU2002109794/15A patent/RU2263516C2/ru not_active IP Right Cessation
- 2000-09-11 CN CNB008128820A patent/CN1222319C/zh not_active Expired - Fee Related
- 2000-09-11 HU HU0202630A patent/HUP0202630A3/hu unknown
- 2000-09-14 US US09/661,696 patent/US6844313B1/en not_active Expired - Fee Related
- 2000-11-09 UA UA2002032077A patent/UA78183C2/uk unknown
-
2002
- 2002-02-19 ZA ZA200201383A patent/ZA200201383B/en unknown
- 2002-03-15 NO NO20021309A patent/NO323694B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0202630A2 (hu) | 2002-12-28 |
| AU781994B2 (en) | 2005-06-23 |
| EP1216059B1 (en) | 2005-10-19 |
| ATE306942T1 (de) | 2005-11-15 |
| WO2001019354A3 (en) | 2001-06-14 |
| RU2263516C2 (ru) | 2005-11-10 |
| NO323694B1 (no) | 2007-06-25 |
| WO2001019354A2 (en) | 2001-03-22 |
| DE60023324T2 (de) | 2006-07-20 |
| AU6985000A (en) | 2001-04-17 |
| UA78183C2 (en) | 2007-03-15 |
| DE60023324D1 (de) | 2005-11-24 |
| PL353968A1 (en) | 2003-12-15 |
| CN1373675A (zh) | 2002-10-09 |
| BR0014058A (pt) | 2004-03-30 |
| CA2382908A1 (en) | 2001-03-22 |
| CZ2002591A3 (cs) | 2002-08-14 |
| KR20020032593A (ko) | 2002-05-03 |
| CN1222319C (zh) | 2005-10-12 |
| EP1216059A2 (en) | 2002-06-26 |
| NO20021309L (no) | 2002-03-15 |
| KR100757909B1 (ko) | 2007-09-11 |
| NO20021309D0 (no) | 2002-03-15 |
| US6844313B1 (en) | 2005-01-18 |
| HUP0202630A3 (en) | 2004-06-28 |
| ZA200201383B (en) | 2002-11-27 |
| MXPA02002439A (es) | 2002-07-30 |
| ES2252048T3 (es) | 2006-05-16 |
| JP2003509365A (ja) | 2003-03-11 |
| IL148234A0 (en) | 2002-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Koehler et al. | Interaction of human sperm with zona‐free hamster eggs: A freeze‐fracture study | |
| Kane | Minimal nutrient requirements for culture of one-cell rabbit embryos | |
| O'Neill | Embryo-derived platelet activating factor: a preimplantation embryo mediator of maternal recognition of pregnancy | |
| Huneau et al. | Estrous sheep serum as a potent agent for ovine IVF: effect on cholesterol efflux from spermatozoa and the acrosome reaction | |
| Hillensjö et al. | Effect of luteinizing hormone and follicle-stimulating hormone on progesterone synthesis by cultured rat cumulus cells | |
| PL202224B1 (pl) | Stała kompozycja farmaceutyczna zawierająca związek HSA | |
| Noguchi et al. | Regulation of hyperactivation of hamster spermatozoa by progesterone | |
| Sananmuang et al. | The effects of roscovitine on cumulus cell apoptosis and the developmental competence of domestic cat oocytes | |
| Haidri et al. | Requirements for the maturation of hamster oocytes from preovulatory follicles | |
| JP2001017160A (ja) | 体外受精用培地組成物 | |
| Koehler et al. | Freeze‐fracture observations on mammalian oocytes | |
| Monroy | Processes controlling sperm—egg fusion | |
| Fujikura et al. | Progesterone and estradiol regulate sperm hyperactivation and in vitro fertilization success in mice | |
| Roy et al. | In vitro inhibition of trophoblast maturation and expansion of early rat blastocysts by an oestrogen antagonist | |
| US6988613B2 (en) | Composition for IVF | |
| TWI281404B (en) | Composition for IVF | |
| Graham et al. | Effect of dilauroylphosphatidylcholine liposomes on motility, induction of the acrosome reaction, and subsequent egg penetration of ram epididymal sperm | |
| Yoshimura et al. | Protein kinase C mediates gonadotropin-releasing hormone agonist-induced meiotic maturation of follicle-enclosed rabbit oocytes | |
| Hosoi et al. | Effects of dibutyryl cyclic AMP on oocyte maturation and ovulation in the perfused rabbit ovary | |
| Petr et al. | Cyclopiazonic acid, an inhibitor of calcium-dependent ATPases, induces exit from metaphase I arrest in growing pig oocytes | |
| JP2004525676A (ja) | Ｉｖｆ組成物 | |
| Müller et al. | Transbilayer motion of spin-labelled phospholipids in the plasma membrane of epididymal and ejaculated ram spermatozoa | |
| Jagiello et al. | A meiotic cytogenetic study in mice of a commonly used tranquilizer reported to concentrate in mammalian follicular fluid | |
| De Felici et al. | Changes in concanavalin A-mediated agglutinability of mouse oocytes during meiosis | |
| DiZio | Amino acid transport, development of cell membrane function, and growth control in early mouse embryogenesis. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20090911 |